TIMI Study Group
@timistudygroup.bsky.social
Providing the latest news and research from the TIMI Study Group, an Academic Research Organization affiliated with Brigham and Women’s Hospital and Harvard Medical School.
Learn about the CORALreef Outcomes-TIMI 77 trial. Can PCSK9i's increase the time to the first occurrence of a major adverse cardiovascular event?
youtu.be/RqqCMlxXqOM
youtu.be/RqqCMlxXqOM
CORALreef Outcomes-TIMI 77 with Dr. Ben Scirica and Dr. David Berg
YouTube video by TIMI Study Group
youtu.be
February 3, 2026 at 9:02 PM
Learn about the CORALreef Outcomes-TIMI 77 trial. Can PCSK9i's increase the time to the first occurrence of a major adverse cardiovascular event?
youtu.be/RqqCMlxXqOM
youtu.be/RqqCMlxXqOM
The Centennial Manuscript – “SEEs in AFib: Data From COMBINE AF” by Samer Al Said et al., out now in Circulation, is the 100th paper published which includes #edoxaban data from the #ENGAGE AF-TIMI 48 trial, which concluded in 2013!
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
American Heart Association Journals
www.ahajournals.org
February 3, 2026 at 5:36 PM
The Centennial Manuscript – “SEEs in AFib: Data From COMBINE AF” by Samer Al Said et al., out now in Circulation, is the 100th paper published which includes #edoxaban data from the #ENGAGE AF-TIMI 48 trial, which concluded in 2013!
www.ahajournals.org/doi/10.1161/...
www.ahajournals.org/doi/10.1161/...
DAPA AC HF - TIMI 68 chosen for "The year in cardiovascular medicine 2025: the top 10 papers in heart failure" in
@ESC_journals
academic.oup.com/eurheartj/ad...
@ESC_journals
academic.oup.com/eurheartj/ad...
The year in cardiovascular medicine 2025: the top 10 papers in heart failure
In 2025, several impactful papers influencing the treatment of patients with heart failure (HF) have been published raising hope that prognosis in these pa
academic.oup.com
January 20, 2026 at 5:34 PM
DAPA AC HF - TIMI 68 chosen for "The year in cardiovascular medicine 2025: the top 10 papers in heart failure" in
@ESC_journals
academic.oup.com/eurheartj/ad...
@ESC_journals
academic.oup.com/eurheartj/ad...
Find out if you should get a Lipoprotein (a) test in this article by
@DrM_ODonoghue
massgeneralbrigham.org/en/about/new...
@DrM_ODonoghue
massgeneralbrigham.org/en/about/new...
Should I Get a Lipoprotein (a) Test? | Mass General Brigham
What does lipoprotein(a) mean for your heart health? Find out who should get an Lp(a) blood test and what to do if you have elevated lipoprotein (a).
massgeneralbrigham.org
January 20, 2026 at 5:33 PM
Find out if you should get a Lipoprotein (a) test in this article by
@DrM_ODonoghue
massgeneralbrigham.org/en/about/new...
@DrM_ODonoghue
massgeneralbrigham.org/en/about/new...
In the latest episode of From the Chairman's Corner, Dr. Marc Sabatine speaks with VESALIUS-CV (TIMI 66) PI Dr. Erin Bohula on the groundbreaking results presented at #AHA25
@EBohula
timi.org/from-the-cha...
@EBohula
timi.org/from-the-cha...
From the Chairman’s Corner
In our new feature, TIMI Chairman Dr. Marc Sabatine discusses exciting trial results with TIMI Investigators Dr. Erin Bohula, PI of the VESALIUS-CV (TIMI 66) trial, discusses the groundbreaking res…
timi.org
December 18, 2025 at 4:42 PM
In the latest episode of From the Chairman's Corner, Dr. Marc Sabatine speaks with VESALIUS-CV (TIMI 66) PI Dr. Erin Bohula on the groundbreaking results presented at #AHA25
@EBohula
timi.org/from-the-cha...
@EBohula
timi.org/from-the-cha...
In #FOURIER, MACE risk ↑ by 11% for every +5 BMI above 30; this excess risk was substantially attenuated by the PCSK9i #evolocumab, underscoring the need to address residual CVD risk in #obesity through intensive #LDL-C ↓ & calls for condition-specific recommendations.
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
Obesity-Associated Cardiovascular Risk and Benefit From PCSK9 Inhibition: A Prespecified Analysis From FOURIER
www.jacc.org
December 11, 2025 at 5:51 PM
In #FOURIER, MACE risk ↑ by 11% for every +5 BMI above 30; this excess risk was substantially attenuated by the PCSK9i #evolocumab, underscoring the need to address residual CVD risk in #obesity through intensive #LDL-C ↓ & calls for condition-specific recommendations.
www.jacc.org/doi/10.1016/...
www.jacc.org/doi/10.1016/...
FOURIER data on the benefit of #PCSK9i #evolocumab in adults with #T1D are now cited in the 2026 @AmDiabetesAssn
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.
diabetesjournals.org/care/article...
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.
diabetesjournals.org/care/article...
American Diabetes Association
American Diabetes Association
diabetesjournals.org
December 9, 2025 at 2:23 PM
FOURIER data on the benefit of #PCSK9i #evolocumab in adults with #T1D are now cited in the 2026 @AmDiabetesAssn
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.
diabetesjournals.org/care/article...
Standards of Care—an important step in an area w/ very limited evidence to guide intensive #LDL-C lowering in T1D.
diabetesjournals.org/care/article...
Dive into the latest in cardiovascular research with 'From the Chairman's Corner', where Dr. Marc Sabatine discusses groundbreaking insights from the CORE and CORE2 TIMI trials and how #olezarsen is reshaping treatment for severe hypertriglyceridemia. timi.org/from-the-cha...
From the Chairman’s Corner
In our new feature, TIMI Chairman Dr. Marc Sabatine discusses exciting trial results with TIMI Investigators Dr. Sabatine discusses the CORE (TIMI 72a) and CORE2 CS6-TIMI 72b AHA 25 LBCT results an…
timi.org
December 2, 2025 at 7:27 PM
Dive into the latest in cardiovascular research with 'From the Chairman's Corner', where Dr. Marc Sabatine discusses groundbreaking insights from the CORE and CORE2 TIMI trials and how #olezarsen is reshaping treatment for severe hypertriglyceridemia. timi.org/from-the-cha...
Drs. Michelle O'Donoghue and Marc Sabatine discuss the ESC Dyslipidemia Guideline Update
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
ESC Dyslipidemia Guideline Update: A US Perspective
Cardiologist Michelle O'Donoghue interviews Marc Sabatine, who was the US representative on the focused update of the ESC lipid management guidelines.
www.medscape.com
October 7, 2025 at 6:03 PM
Drs. Michelle O'Donoghue and Marc Sabatine discuss the ESC Dyslipidemia Guideline Update
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
Icosapent ethyl reduces MI across MI subtypes and sizes of MI in statin-treated patients with elevated TGs at increased CV risk
academic.oup.com/eurjpc/advan...
academic.oup.com/eurjpc/advan...
Benefit of Icosapent Ethyl Across Types and Sizes of Myocardial Infarction in REDUCE-IT
AbstractAims. We studied the efficacy and safety of icosapent ethyl (IPE) 4g daily in reducing the risk of myocardial infarction (MI) across different MI s
academic.oup.com
October 6, 2025 at 5:41 PM
Icosapent ethyl reduces MI across MI subtypes and sizes of MI in statin-treated patients with elevated TGs at increased CV risk
academic.oup.com/eurjpc/advan...
academic.oup.com/eurjpc/advan...
Coverage in TCTMD of GARDEN-TIMI 74 results
www.tctmd.com/news/lowerin...
www.tctmd.com/news/lowerin...
Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74
Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, why?
www.tctmd.com
October 2, 2025 at 6:36 PM
Coverage in TCTMD of GARDEN-TIMI 74 results
www.tctmd.com/news/lowerin...
www.tctmd.com/news/lowerin...
GOLDILOX-TIMI 69 results now in Nat Med. No effects of LOX-1 inhibition on coronary plaque volume.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial - Nature Medicine
In a randomized trial of patients with a previous myocardial infarction and with residual inflammation, a monoclonal antibody targeting the LOX-1 receptor, thought to contribute to atherosclerotic plaque progression and inflammation, reduced soluble LOX-1 and interleukin-6 levels but did not lead to a substantial reduction in coronary plaque volume.
www.nature.com
September 25, 2025 at 2:00 PM
GOLDILOX-TIMI 69 results now in Nat Med. No effects of LOX-1 inhibition on coronary plaque volume.
www.nature.com/articles/s41...
www.nature.com/articles/s41...